Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
Jo Ann Wilson, San Francisco, CA (US); and Khalid Shah, Half Moon Bay, CA (US)
Assigned to Exelixis, Inc., Alameda, CA (US)
Filed by Exelixis, Inc., Alameda, CA (US)
Filed on Feb. 8, 2024, as Appl. No. 18/436,836.
Application 16/706,323 is a division of application No. 16/151,653, filed on Oct. 4, 2018, granted, now 10,543,206, issued on Jan. 28, 2020.
Application 16/151,653 is a division of application No. 15/348,716, filed on Nov. 10, 2016, granted, now 10,123,999, issued on Nov. 13, 2018.
Application 15/348,716 is a division of application No. 13/984,559, granted, now 9,717,720, issued on Aug. 1, 2017, previously published as PCT/US2012/024591, filed on Feb. 10, 2012.
Application 18/436,836 is a continuation of application No. 18/462,739, filed on Sep. 7, 2023.
Application 18/462,739 is a continuation of application No. 17/679,634, filed on Feb. 24, 2022, abandoned.
Application 17/679,634 is a continuation of application No. 17/170,275, filed on Feb. 8, 2021, granted, now 11,298,349, issued on Apr. 12, 2022.
Application 17/170,275 is a continuation of application No. 17/152,394, filed on Jan. 19, 2021, abandoned.
Application 17/152,394 is a continuation of application No. 16/706,323, filed on Dec. 6, 2019, abandoned.
Claims priority of provisional application 61/441,520, filed on Feb. 10, 2011.
Claims priority of provisional application 61/441,527, filed on Feb. 10, 2011.
Prior Publication US 2024/0189298 A1, Jun. 13, 2024
1. A pharmaceutical composition for oral administration comprising Compound IB:
and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is a tablet or a capsule, and wherein the pharmaceutical composition contains 100 ppm or less of 6,7-dimethoxy-quinoline-4-ol.
